BSE Live
Apr 10, 16:01Prev. Close
7.68
Open Price
7.66
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Profit & Loss account of DECIPHER LABS (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 0.85 | 3.27 | 0.65 | 0.99 | 0.44 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 0.85 | 3.27 | 0.65 | 0.99 | 0.44 | |
| Total Operating Revenues | 0.85 | 3.53 | 0.81 | 0.99 | 0.98 | |
| Other Income | 0.02 | 0.02 | 0.03 | 0.05 | 0.14 | |
| Total Revenue | 0.88 | 3.55 | 0.84 | 1.03 | 1.12 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | |
| Purchase Of Stock-In Trade | 0.67 | 3.14 | 0.47 | 0.16 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.00 | 0.00 | 0.04 | 0.00 | 0.27 | |
| Employee Benefit Expenses | 0.23 | 0.17 | 0.20 | 0.23 | 0.20 | |
| Finance Costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | |
| Depreciation And Amortisation Expenses | 0.02 | 0.01 | 0.06 | 0.05 | 0.04 | |
| Other Expenses | 0.39 | 0.20 | 0.46 | 0.24 | 0.34 | |
| Total Expenses | 1.32 | 3.53 | 1.24 | 0.68 | 1.02 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -0.44 | 0.03 | -0.40 | 0.36 | 0.10 | |
| Exceptional Items | 0.00 | 0.00 | -2.24 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -0.44 | 0.03 | -2.64 | 0.36 | 0.10 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -0.44 | 0.02 | -2.62 | 0.36 | 0.10 | |
| Profit/Loss From Continuing Operations | -0.44 | 0.02 | -2.62 | 0.36 | 0.10 | |
| Profit/Loss For The Period | -0.44 | 0.02 | -2.62 | 0.36 | 0.10 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -0.44 | 0.02 | -2.59 | 0.36 | 0.10 | |
| Diluted EPS (Rs.) | -0.44 | 0.02 | -2.59 | 0.36 | 0.10 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth